Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Income towards Parent Company: 2021-2025

Historic Income towards Parent Company for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to -$52.8 million.

  • Prime Medicine's Income towards Parent Company fell 0.60% to -$52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$199.6 million, marking a year-over-year increase of 8.97%. This contributed to the annual value of -$195.9 million for FY2024, which is 1.14% up from last year.
  • As of Q3 2025, Prime Medicine's Income towards Parent Company stood at -$52.8 million, which was down 0.46% from -$52.6 million recorded in Q2 2025.
  • Prime Medicine's Income towards Parent Company's 5-year high stood at -$16.4 million during Q3 2021, with a 5-year trough of -$65.6 million in Q4 2023.
  • In the last 3 years, Prime Medicine's Income towards Parent Company had a median value of -$51.9 million in 2025 and averaged -$50.1 million.
  • The largest annual percentage gain for Prime Medicine's Income towards Parent Company in the last 5 years was 37.54% (2022), contrasted with its biggest fall of 78.83% (2022).
  • Prime Medicine's Income towards Parent Company (Quarterly) stood at -$62.9 million in 2021, then soared by 37.54% to -$39.3 million in 2022, then tumbled by 67.10% to -$65.6 million in 2023, then surged by 35.60% to -$42.3 million in 2024, then fell by 0.60% to -$52.8 million in 2025.
  • Its last three reported values are -$52.8 million in Q3 2025, -$52.6 million for Q2 2025, and -$51.9 million during Q1 2025.